1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.
2. Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry2000;157:669–682.
[PubMed] 3. Alonso J, Lépine JP. Overview of key data from the European Study of the Epidemiology of Mental Disorders. J Clin Psychiatry2007;68:3–9.
4. Oakley-Browne M, Wells E, Scott K, et al. The New Zealand Mental Health Survey. Ministry of Health, Wellington, 2006.
5. Jordanova V, Wickramesinghe C, Gerada C, et al. Validation of two survey diagnostic interviews among primary care attendees: a comparison of CIS-R and CIDI with SCAN ICD-10 diagnostic categories. Psychol Med2004;34:1013–1024.
6. Green H, McGinnity A, Meltzer H, et al. Mental health of children and young people in Great Britain, 2004. Available at http://www.ic.nhs.uk/webfiles/publications/mentalhealth04/MentalHealthChildrenYoungPeople310805_PDF.pdf (last accessed 16 September 2011).
7. Lim L, Ng TP, Chua HC, et al. Generalised anxiety disorder in Singapore: prevalence, co-morbidity and risk factors in a multi-ethnic population. Soc Psychiatry Psychiatr Epidemiol2005;40:972–979.
[PubMed] 8. Olatunji BO, Cisler JM, Tolin DF, et al. Quality of life in the anxiety disorders: a meta-analytic review. Clin Psychol Rev2007;27:572–581.
[PubMed] 9. Lau AW, Edelstein BA, Larkin KT. Psychophysiological arousal in older adults: a critical review. Clin Psychol Rev2001;21:609–630.
[PubMed] 10. Brantley PJ, Mehan DJ Jr, Ames SC, et al. Minor stressors and generalised anxiety disorders among low income patients attending primary care clinics. J Nerv Ment Dis1999;187:435–440.
[PubMed] 11. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the national comorbidity survey. Arch Gen Psychiatry1994;51:8–19.
[PubMed] 12. Brown ES, Fulton MK, Wilkeson A, et al. The psychiatric sequelae of civilian trauma. Comp Psychiatry2000;41:19–23.
[PubMed] 13. Hawker DSJ, Boulton MJ. Twenty years' research on peer victimisation and psychosocial maladjustment: a meta-analytic review of cross-sectional studies. J Child Psychol Psychiatr 2000;41:441–445. Search date 1997. [PubMed] 14. Hettema JM, Neale MC, Kendler KS. A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry2001;158:1568–1578. Search date not reported.
[PubMed] 15. Middeldorf CM, Cath CD, Van Dyck R, et al. The co-morbidity of anxiety and depression in the perspective of genetic epidemiology: a review of twin and family studies. Psychol Med2005;35:611–624. Search date 2003.
[PubMed] 16. Kessler RD, Wittchen HU. Patterns and correlates of generalized anxiety disorder in community samples. J Clin Psychiatry 2002;63(suppl 8):4–10. [PubMed] 17. Yonkers KA, Dyck IR, Warshaw M, et al. Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry2000;176:544–549.
18. Gould RA, Otto MW, Pollack MH, et al. Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: a preliminary meta-analysis. Behav Ther 1997;28:285–305. Search date 1996.
19. Westen D, Morrison K. A multidimensional meta-analysis of treatments for depression, panic and generalized anxiety disorder: an empirical examination of the status of empirically supported therapies. J Consult Clin Psychol2001;69:875–889. Search date not reported but only included studies published 1990–1999.
[PubMed] 20. Hunot V, Churchill R, Silva de Lima M, et al. Psychological therapies for generalised anxiety disorder. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2006.
[PubMed] 21. Covin R, Ouimet AJ, Seeds PM, et al. A meta-analysis of CBT for pathological worry among clients with GAD. J Anxiety Disord2008;22:108–116. Search date 2006.
[PubMed] 22. Hendriks GJ, Oude Voshaar RC, Keijsers GP, et al. Cognitive-behavioural therapy for late-life anxiety disorders: a systematic review and meta-analysis. Acta Psychiatr Scand2008;117:403–411.
[PubMed] 23. Hofmann SG, Smits JA. Cognitive-behavioral therapy for adult anxiety disorders: a meta-analysis of randomized placebo-controlled trials. J Clin Psychiatry2008;69:621–632.
[PMC free article] [PubMed] 24. Stanley MA, Wilson NL, Novy DM, et al. Cognitive behavior therapy for generalized anxiety disorder among older adults in primary care: a randomized clinical trial. JAMA2009;301:1460–1467.
[PMC free article] [PubMed] 25. Dugas MJ, Brillon P, Savard P, et al. A randomized clinical trial of cognitive-behavioral therapy and applied relaxation for adults with generalized anxiety disorder. Behav Ther2010;41:46–58.
[PMC free article] [PubMed] 26. Leichsenring F, Salzer S, Jaeger U, et al. Short-term psychodynamic psychotherapy and cognitive-behavioral therapy in generalized anxiety disorder: a randomized, controlled trial. Am J Psychiatry2009;166:875–881.
[PubMed] 27. Borkovec TD, Newman MG, Pincus AL, et al. A component analysis of cognitive-behavioural therapy for generalized anxiety disorder and the role of interpersonal process. J Consult Clin Psychol2002;70:288–298.
[PubMed] 28. Gosselin P, Ladouceur R, Morin CM, et al. Benzodiazepine discontinuation among adults with GAD: a randomized trial of cognitive-behavioral therapy. J Consult Clin Psychol2006;74:908–919.
[PubMed] 29. Fisher PL, Durham RC. Recovery rates in generalized anxiety disorder following psychological therapy: an analysis of clinically significant change in the STAI-T across outcome studies since 1990. Psychol Med1999;29:1425–1434. Search date 1998.
[PubMed] 30. Mitte K, Noack P, Steil R, Hautzinger M. A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder. J Clin Psychopharmacol2005;25:141–150. Search date 2002.
[PubMed] 31. Rickels K, DeMartinis N, Aufdembrinke B. A double-blind, placebo controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder. J Clin Psychopharmacol2000;20:12–18.
32. Figueira ML. Alprazolam SR in the treatment of generalised anxiety: a multicentre controlled study with bromazepam. Hum Psychother 1999;14:171–177.
33. Vaz-Serra A, Figuerra L, Bessa-Peixoto A, et al. Mexazolam and alprazolam in the treatment of generalized anxiety disorder. Clin Drug Invest 2001;21:257–263.
34. Bandelow B, Seidler-Brandler U, Becker A, et al. Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World J Biol Psychiatry2007;8:175–187.
[PubMed] 35. Mahe V, Balogh A. Long-term pharmacological treatment of generalized anxiety disorder. Int Clin Psychopharmacol2000;15:99–105. Search date 1998.
36. Tyrer P. Current problems with the benzodiazepines. In: Wheatly D, ed. The anxiolytic jungle: where next? Chichester: Wiley, 1990:23–47.
37. Kilic C, Curran HV, Noshirvani H, et al. Long-term effects of alprazolam on memory: a 3.5 year follow-up of agoraphobia/panic patients. Psychol Med1999;29:225–231.
[PubMed] 38. Thomas RE. Benzodiazepine use and motor vehicle accidents. Systematic review of reported association. Can Fam Physician1998;44:799–808. Search date 1997.
[PMC free article] [PubMed] 39. Dolovich LR, Addis A, Regis Vaillancourt JD, et al. Benzodiazepine use in pregnancy and major malformations of oral cleft: meta-analysis of cohort and case-control studies. BMJ1998;317:839–843. Search date 1997.
[PMC free article] [PubMed]
40. Bernstein JG. Handbook of drug therapy in psychiatry, 3rd ed. St Louis, MO: Mosby Year Book, 1995:401.
41. DeMartinis N, Rynn M, Rickels K, et al. Prior benzodiazepine use and buspirone response in the treatment of generalized anxiety disorder. J Clin Psychiatry2000;61:91–94.
[PubMed] 42. Chessick CA, Allen MH, Thase M, et al. Azapirones for generalized anxiety disorder. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2005.
[PubMed] 43. Rickels K, Weisman K, Norstad N, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry1982;12:81–86.
[PubMed] 44. Sinclair LI, Christmas DM, Hood SD, et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry2009;194:483–490.
45. Guaiana G, Barbui C, Cipriani A, et al. Hydroxyzine for generalised anxiety disorder. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2010.
46. Lew BL, Haw CR, Lee MH. Cutaneous drug eruption from cetirizine and hydroxyzine. J Am Acad Dermatol2004;50:953–956.
[PubMed] 47. Wong AR, Rasool AH. Hydroxyzine-induced supraventricular tachycardia in a nine-year-old child. Singapore Med J2004;45:90–92.
[PubMed] 48. Yanagawa Y, Ohshita T, Takemoto M, et al. A case of catatonia associated with the ingestion of hydroxyzine. No To Shinkei2005;57:45–49.
[PubMed] 49. Serreau R, Komiha M, Blanc F, et al. Neonatal seizures associated with maternal hydroxyzine hydrochloride in late pregnancy. Reprod Toxicol2005;20:573–574.
[PubMed] 50. Ballenger JC, McDonald S, Noyes R, et al. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist, abecarnil (ZK 112-119) in generalised anxiety disorder. Adv Biochem Psychopharmacol1992;47:431–447.
[PubMed] 51. Kapczinski F, Lima MS, Souza JS, et al. Antidepressants for generalized anxiety disorder. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2002.
[PubMed] 52. Donovan MR, Glue P, Kolluri S, et al. Comparative efficacy of antidepressants in preventing relapse in anxiety disorders - a meta-analysis. J Affect Dis2010;123:9–16.
[PubMed] 53. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalised anxiety disorder: a placebo-controlled comparison of imipramine, trazodone and diazepam. Arch Gen Psychiatry1993;50:884–895.
[PubMed] 54. Mancini M, Perna G, Rossi A, et al. Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: a review of the literature. Expert Opin Pharmacother2010;11:1167–1181.
[PubMed] 55. Davidson JR, Wittchen HU, Llorca PM, et al. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. Eur Neuropsychopharmacol2008;18:673–681.
[PubMed] 56. Davidson JR, Bose A, Korotzer A, et al. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety2004;19:234–240.
[PubMed] 57. Baldwin DS, Huusom AKT, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: Randomised, placebo-controlled, double-blind study. Br J Psychiatry2006;189:264–272.
[PubMed] 58. Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol2006;9:495–505.
[PubMed] 59. Bose A, Korotzer A, Gommoll C, et al. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depress Anxiety2008;25:854–861.
[PubMed] 60. Lenze EJ, Rollman BL, Shear MK, et al. Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. JAMA2009;301:295–303.
[PMC free article] [PubMed] 61. Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Dis2005:87:161–167.
[PubMed] 62. Moller HJ, Volz HP, Reimann IW, et al. Opipramol for the treatment of generalised anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol2001;21:51–65.
[PubMed] 63. Rickels K, Zaninelli R, McCafferty J, et al. Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry2003;160:749–756.
[PubMed] 64. Allgulander C, Dahl AA, Austin C, et al. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry2004;161:1642–1649.
[PubMed] 65. Dahl AA, Raindran A, Allgulander C, et al. Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors. Acta Psychiatr Scand2005;111:429–435.
[PubMed] 66. Brawman-Mintzer O, Knapp RG, Rynn M, et al. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry2006;67:874–881.
[PubMed] 67. Nimatoudis I, Zissis NP, Kogeorgos J, et al. Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study. Int Clin Psychopharmacol2004;19:331–336.
[PubMed] 68. Lenox-Smith AJ, Reynolds A. A double-blind, randomised, placebo-controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br J Gen Pract2003;53:772–777.
[PMC free article] [PubMed] 69. Montgomery SA, Tobias K, Zornberg GL, et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry2006;67:771–782.
[PubMed] 70. Davidson JR, DuPont RL, Hedges D, et al. Efficacy, safety and tolerability of venlafaxine extended release and buspirone in outpatients with generalised anxiety disorder. J Clin Psychiatry1999;60:528–535.
[PubMed] 71. Boyer P, Mahe V, Hackett D. Social adjustment in generalised anxiety disorder: a long-term placebo-controlled study of venlafaxine extended release. Eur Psychiatry2004;19:272–279.
[PubMed] 72. Bielski R, Bose A. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005;17:85–89. [PubMed] 73. Ball SG, Kuhn A, Wall D, et al. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind prospective comparison between paroxetine and sertraline. J Clin Psychiatry2005;66:94–99.
[PubMed] 74. Rocca P, Fonzo V, Scotta M, et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand1997;95:444–450.
75. Cui W, Zhang P, Wang D. A comparative study of paroxetine and lorazepam in the treatment of generalized anxiety disorder. Chin Mental Health J 2005;18:741.
76. Stein D, Andersen H, Goodman W. Escitalopram for the treatment of GAD: efficacy across different subgroups and outcomes. Ann Clin Psychiatry2005;17:71–75.
[PubMed] 77. Baldwin D, Woods R, Lawson R, et al. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ2011;342:d1199.
[PubMed] 78. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry1998;44:77–87.
[PubMed] 79. Dukes PD, Robinson GM, Thomson KJ, et al. Wellington coroner autopsy cases 1970–89: acute deaths due to drugs, alcohol and poisons. N Z Med J1992;105:25–27. [Erratum in N Z Med J 1992;105:135]
[PubMed] 80. Kerr GW, McGuffie AC, Wilkie S. Tricyclic antidepressant overdose: a review. Emerg Med J2001;18:236–241.
[PMC free article] [PubMed] 81. Pearn J, Nixon J, Ansford A, et al. Accidental poisoning in childhood: five year urban population study with 15 year analysis of fatality. BMJ1984;288:44–46.
[PMC free article] [PubMed] 82. Liu BA, Mittmann N, Knowles SR, et al. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. Can Med Assoc J 1995;155:519–527. [Erratum in Can Med Assoc J1996;155:1043]
[PMC free article] [PubMed] 83. Thapa PB, Gideon P, Cost TW, et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med1998;339:875–882.
[PubMed] 84. Liu B, Anderson G, Mittmann N, et al. Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet1998;351:1303–1307.
[PubMed] 85. Kulin NA, Pastuszak A, Koren G. Are the new SSRIs safe for pregnant women? Can Fam Physician1998;44;2081–2083.
[PMC free article] [PubMed]
86. Medicines and Healthcare products Regulatory Agency. Paroxetine (Seroxat): safety in pregnancy. http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON2022698 (last accessed 16 September 2011).
87. Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicentre study of 1022 outpatients. J Clin Psychiatry 2000;62(suppl 3):10–21. [PubMed] 88. Gao K, Muzina D, Gajwani P, et al. Efficacy of typical and atypical antipsychotics for primary and comorbid anxiety symptoms or disorders: a review. J Clin Psychiatry2006;67:1327–1340.
89. Depping AM, Komossa K, Kissling W, et al. Second-generation antipsychotics for anxiety disorders. In: The Cochrane Library, Issue 2, 2011. Chichester, UK:
John Wiley & Sons, Ltd. Search date 2010.
90. Mendels J, Krajewski TF, Huffer V, et al. Effective short-term treatment of generalized anxiety with trifluoperazine. J Clin Psychiatry1986;47:170–174.
[PubMed] 91. Tassone DM, Boyce E, Guyer J, et al. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther2007;29:26–48.
[PubMed] 92. Feltner DE, Crockatt JG, Dubovsky SJ, et al. A raondomized double-blind, placebo-controlled, fixed-dose, multicenter study of Pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol2003;23:240–249.
[PubMed] 93. Rickels K, Pollack MH, Feltner DE, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry2005;62:1022–1030.
[PubMed] 94. Montgomery S, Chatamra K, Pauer L, et al. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry2008;193:389–394.
[PubMed] 95. Cartwright-Hatton S, Roberts C, Chitsabesan P, et al. Systematic review of the efficacy of cognitive behaviour therapies for childhood and adolescent anxiety disorders. Br J Clin Psychol2004;43:421–436. Search date 2003.
[PubMed] 96. Compton SN, March JS, Brent D, et al. Cognitive-behavioral psychotherapy for anxiety and depressive disorders in children and adolescents: an evidence-based medicine review. J Am Acad Child Adolesc Psychiatry2004;43:930–959. Search date 2002.
[PubMed] 97. James A, Soler A, Weatherall R. Cognitive behavioural therapy for anxiety disorders in children and adolescents. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2004.
[PubMed] 98. Richardson T, Stallard P, Velleman S. Computerised cognitive behavioural therapy for the prevention and treatment of depression and anxiety in children and adolescents: a systematic review. Clin Child Fam Psychol Rev2010;13:275–290.
99. Flannery-Schroeder EC, Kendall PC. Group and individual cognitive-behavioral treatments for youth with anxiety disorders: a randomized clinical trial. Cognitive Ther Res 2000;24:251–278.
100. Shortt AL, Barrett PM, Fox TL, et al. Evaluating the FRIENDS program: a cognitive-behavioral group treatment for anxious children and their parents. J Clin Child Psychol2001;30:525–535.
[PubMed] 101. Spence SH, Holmes JM, March S, et al. The feasibility and outcome of clinic plus internet delivery of cognitive-behavior therapy for childhood anxiety. J Consult Clin Psychol2006;74:614–621.
[PubMed] 102. March S, Spence SH, Donovan CL. The efficacy of an internet-based cognitive-behavioral therapy intervention for child anxiety disorders. J Pediatr Psychol2009;34:474–487.
[PubMed] 103. Bernstein GA, Layne AE, Egan EA, et al. School-based interventions for anxious children. J Am Acad Child Adolesc Psychiatry2005;44:1118–1127.
[PMC free article] [PubMed] 104. Lyneham HJ, Rapee RM. Evaluation of therapist-supported parent-implemented CBT for anxiety disorders in rural children. Behav Res Ther2006;44:1287–1300.
[PubMed] 105. Rapee RM, Abbott MJ, Lyneham HJ, et al. Bibliotherapy for children with anxiety disorders using written materials for parents: a randomized controlled trial. J Consult Clin Psychol2006;74:436–444.
[PubMed] 106. Kendall PC, Hudson JL, Gosch E, et al. Cognitive-behavioral therapy for anxiety disordered youth: a randomized clinical trial evaluating child and family modalities. J Consult Clin Psychol2008;76:282–297.
[PubMed] 107. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med2008;359:2753–2766.
[PMC free article] [PubMed] 108. Hudson JL, Rapee RM, Deveney C, et al. Cognitive-behavioral treatment versus an active control for children and adolescents with anxiety disorders: a randomized trial. J Am Acad Child Adolesc Psychiatry2009;48:533–544.
[PubMed] 109. Hirshfeld-Becker DR, Masek B, Henin A, et al. Cognitive behavioral therapy for 4- to 7-year-old children with anxiety disorders: a randomized clinical trial. J Consult Clin Psychol2010;78:498–510.
[PubMed] 110. Lau WY, Chan CK, Li JC, et al. Effectiveness of group cognitive-behavioral treatment for childhood anxiety in community clinics. Behav Res Ther2010;48:1067–1077.
[PubMed] 111. Silverman WK, Kurtines WM, Jaccard J, et al. Directionality of change in youth anxiety treatment involving parents: an initial examination. J Consult Clin Psychol2009;77:474–485.
[PMC free article] [PubMed] 112. Liber JM, Van Widenfelt BM, Utens EM, et al. No differences between group versus individual treatment of childhood anxiety disorders in a randomised clinical trial. J Child Psychol Psychiatry2008;49:886–893.
[PubMed] 113. Simeon JG, Ferguson HB, Knott V, et al. Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders. J Am Acad Child Adolesc Psychiatry1992;31:29–33.
114. Ipser JCS. Pharmacotherapy for anxiety disorders in children and adolescents. In: The Cochrane Library, Issue 2, 2011. Chichester, UK: John Wiley & Sons, Ltd. Search date 2008.
115. Birmaher B, Axelson DA, Monk K, et al. Fluoxetine for the treatment of childhood anxiety disorders. J American Acad Child Adolesc Psychiatry2003;42:415–423.
[PubMed] 116. Pine DS, Walkup JT, Labelarte MJ, et al. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med2001;344:1279–1285.
[PubMed] 117. Rynn MA, Siqueland L, Rickels K, et al. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry2001;158:2008–2014.
[PubMed] 118. Ginsburg GS, Riddle MA, Davies M, et al. Somatic symptoms in children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry2006;45:1179–1187.
[PubMed] 119. Alfano CA, Ginsburg GS, Kingery JN, et al. Sleep-related problems among children and adolescents with anxiety disorders. J Am Acad Child Adolesc Psychiatry2007;46:224–232.
[PubMed] 120. Hammad TA, Laughren T, Racoosin J, et al. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry2006;63:332–339.
[PubMed] 121. Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA2007;297:1683–1696.